Cancer signal origin (CSO) prediction in cancer of unknown primary (CUP) syndrome (CRONUS) using circulating tumor DNA (ctDNA) Content Editor Cancer signal origin (CSO) prediction in cancer of unknown primary (CUP) syndrome (CRONUS) using circulating tumor DNA (ctDNA) Read More »
Safety and Performance of a Multi-Cancer Early Detection (MCED) Test in an Intended Use Population: Initial Results from the Registrational PATHFINDER 2 Study Content Editor Safety and Performance of a Multi-Cancer Early Detection (MCED) Test in an Intended Use Population: Initial Results from the Registrational PATHFINDER 2 Study Read More »
Clinical Performance of a Blood-Only, Targeted Methylation Circulating Tumor DNA (ct DNA) Assay for Minimal Residual Disease (MRD) Detection in Colorectal Cancer (CRD) Content Editor Clinical Performance of a Blood-Only, Targeted Methylation Circulating Tumor DNA (ct DNA) Assay for Minimal Residual Disease (MRD) Detection in Colorectal Cancer (CRD) Read More »
Tumor-Agnostic Detection and Monitoring of Circulating Tumor DNA in HER2-positive Early Breast Cancer Grail Content Editor Tumor-Agnostic Detection and Monitoring of Circulating Tumor DNA in HER2-positive Early Breast Cancer Read More »
Cell-free DNA Indicates Potential Preclinical Detectability of Cancer Signals up to 30 Months Prior to Diagnosis Grail Content Editor Cell-free DNA Indicates Potential Preclinical Detectability of Cancer Signals up to 30 Months Prior to Diagnosis Read More »
Early Real-World Experience With Positive Multi-Cancer Early Detection (MCED) Test Cases and Negative Initial Diagnostic Work-Up Grail Content Editor Early Real-World Experience With Positive Multi-Cancer Early Detection (MCED) Test Cases and Negative Initial Diagnostic Work-Up Read More »
Impact of Multicancer Early Detection (MCED) Test on Participant-Reported Outcomes (PRO) and Behavioral Intentions by Cancer Risk Grail Content Editor Impact of Multicancer Early Detection (MCED) Test on Participant-Reported Outcomes (PRO) and Behavioral Intentions by Cancer Risk Read More »
Modeled Economic and Clinical Impact of a Multi-Cancer Early Detection (MCED) Test in a Population with Hereditary Cancer Syndromes Grail Content Editor Modeled Economic and Clinical Impact of a Multi-Cancer Early Detection (MCED) Test in a Population with Hereditary Cancer Syndromes Read More »
Circulating Tumour DNA (ctDNA) Clearance With Neoadjuvant Durvalumab (D) + Tremelimumab (T) + Enfortumab Vedotin (EV) for Cisplatin-Ineligible Treatment of Muscle-Invasive Bladder Cancer(MIBC) From the Safety Run-in Cohort of the Phase 3 VOLGA Trial Grail Content Editor Circulating Tumour DNA (ctDNA) Clearance With Neoadjuvant Durvalumab (D) + Tremelimumab (T) + Enfortumab Vedotin (EV) for Cisplatin-Ineligible Treatment of Muscle-Invasive Bladder Cancer(MIBC) From the Safety Run-in Cohort of the Phase 3 VOLGA Trial Read More »
Circulating tumor DNA dynamics and treatment responses in chemotherapy-ineligible patients with unresectable Stage III NSCLC from the phase 2 DUART trial Grail Content Editor Circulating tumor DNA dynamics and treatment responses in chemotherapy-ineligible patients with unresectable Stage III NSCLC from the phase 2 DUART trial Read More »
